Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.88

€1.88

-2.580%
-0.048
-2.580%
-
 
27.03.26 / Tradegate WKN: A40AEG / Name: Pentixapharm Holding / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Pentixapharm Holding AG Stock

A loss of -2.580% shows a downward development for Pentixapharm Holding AG.

Pros and Cons of Pentixapharm Holding AG in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension